RELGAABI Drug Patent Profile
When do Relgaabi patents expire, and what generic alternatives are available?
Relgaabi is a drug marketed by Sciegen Pharms and is included in one NDA.
The generic ingredient in RELGAABI is gabapentin. There is one drug master file entry for this compound. Eighty-nine suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Relgaabi
A generic version of RELGAABI was approved as gabapentin by ACTAVIS ELIZABETH on September 12th, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RELGAABI?
- What are the global sales for RELGAABI?
- What is Average Wholesale Price for RELGAABI?
Summary for RELGAABI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 24 |
| Drug Prices: | Drug price information for RELGAABI |
| DailyMed Link: | RELGAABI at DailyMed |
Pharmacology for RELGAABI
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for RELGAABI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sciegen Pharms | RELGAABI | gabapentin | CAPSULE;ORAL | 204989-001 | Feb 18, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sciegen Pharms | RELGAABI | gabapentin | CAPSULE;ORAL | 204989-003 | Feb 18, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sciegen Pharms | RELGAABI | gabapentin | CAPSULE;ORAL | 204989-004 | Mar 6, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sciegen Pharms | RELGAABI | gabapentin | CAPSULE;ORAL | 204989-002 | Feb 18, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
